Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1.0%
    Check dated 2025-07-04T02:41:57.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:11:00.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T08:06:51.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:40:59.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:49.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page has been updated to include new collaborators, specifically Eli Lilly and Company, and a revision number change from v2.14.4 to v2.15.0. Additionally, the title of the study has been modified to emphasize the focus on Head and Neck Squamous Cell Carcinoma.
    Difference
    32%
    Check dated 2025-04-16T02:01:23.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.